Skip to content
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact
XOMA
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Company & Partner News
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Financial Information
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Overview
    • Charts
    • Historical Data
    • IRS Form 8937
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

Mar 07, 2018 4:05pm EST

XOMA to Present at the Cowen and Company 38th Annual Health Care Conference

Mar 05, 2018 7:00am EST

XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel

Jan 08, 2018 7:00am EST

XOMA Announces Exclusive License Agreement for XOMA 358 with Rezolute, Inc.

Dec 07, 2017 8:35am EST

XOMA Reports Third Quarter 2017 Financial Results

Nov 06, 2017 4:05pm EST

XOMA Announces Multiple New License Agreements for Proprietary Phage Display Libraries

Oct 04, 2017 9:15am EDT

XOMA to Present at the Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2017 7:00am EDT

XOMA Earns $3 Million Milestone Payment from its License Agreement with Nanotherapeutics

Sep 11, 2017 7:00am EDT

XOMA to Present at the Rodman and Renshaw 19th Annual Global Investment Conference

Sep 06, 2017 7:00am EDT

XOMA Announces Transformational License Agreements for Gevokizumab and its IL-1 Beta Intellectual Property Portfolio

Aug 25, 2017 7:00am EDT
RSS
  • Prev
    • 1...
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • ...47
    Next
    • Email Alerts
    • RSS News Feed
    • Terms of Use

    © 2025 XOMA Royalty Corporation.  All rights reserved.

    All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

    • Follow us:
    © 2025 XOMA • Powered by GeneratePress
    Scroll back to top